{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:12:40Z","timestamp":1781881960851,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clml.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T22:19:06Z","timestamp":1647469146000},"page":"618-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real World Long-term Follow-up Experience with Yttrium-90\u00a0ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.03.004_bib0001","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2022.03.004_bib0002","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.03.004_bib0003","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.03.004_bib0004","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.03.004_bib0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2013.11.225","article-title":"Radiation therapy administration and survival in stage I\/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"88","author":"Olszewski","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2022.03.004_bib0006","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/annonc\/mdn668","article-title":"Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy","volume":"20","author":"Gobbi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0007","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"Nadler","year":"1981","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clml.2022.03.004_bib0008","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0009","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy vs. rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0010","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0011","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.03.004_bib0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2022.03.004_bib0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","author":"Samaniego","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clml.2022.03.004_bib0015","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1080\/10428194.2020.1802449","article-title":"Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma","volume":"61","author":"Lossos","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clml.2022.03.004_bib0016","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12695","article-title":"Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study","volume":"164","author":"Ibatici","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clml.2022.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0018","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study","volume":"93","author":"Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2022.03.004_bib0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/ph12040141","article-title":"Radioimmunotherapy in non-hodgkin\u2019s lymphoma: retrospective adverse event profiling of zevalin and Bexxar","volume":"12","author":"Sachpekidis","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clml.2022.03.004_bib0020","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.03.004_bib0021","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.14688","article-title":"Risk of histological transformation and therapy-related myelodysplasia\/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma","volume":"178","author":"Epperla","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clml.2022.03.004_bib0022","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0023","first-page":"478","article-title":"Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia","volume":"19","author":"Schilder","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.clml.2022.03.004_bib0024","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000486788","article-title":"Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy after cytoreduction with ESHAP chemotherapy in patients with relapsed follicular non-hodgkin lymphoma: final results of a phase ii study","volume":"94","author":"Puvvada","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2022.03.004_bib0025","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.03.004_bib0026","year":"2017","journal-title":"Common Terminology Criteria for Adverse Events. Version 5.0"},{"key":"10.1016\/j.clml.2022.03.004_bib0027","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1038\/s41375-020-0798-9","article-title":"Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study","volume":"34","author":"Di","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.03.004_bib0028","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-022-04781-3","article-title":"90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years","volume":"101","author":"Rieger","year":"2022","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2022.03.004_bib0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0360-3016(01)01952-6","article-title":"Zevalin radioimmunotherapy is effective for patients with bulky non-Hodgkin's lymphoma","volume":"51","author":"Meredith","year":"2001","journal-title":"Int Radiat Oncol*Biol*Physic"},{"key":"10.1016\/j.clml.2022.03.004_bib0030","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2009.12.030","article-title":"External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma","volume":"79","author":"Burdick","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2022.03.004_bib0031","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2010.09.044","article-title":"Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy","volume":"82","author":"Smith","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2022.03.004_bib0032","series-title":"Alhaj Moustafa M. CD20-Targeted Systemic Radio-Immunotherapy With Yttrium-90 Ibritumomab Tiuxetan For Low Grade Non-Hodgkin Lymphomas [M.S.]","year":"2021"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:23Z","timestamp":1761871223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2152265022000854"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.03.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Long-term Follow-up Experience with Yttrium-90\u00a0ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}